Abingdon Health PLC (GB:ABDX)
LSE:ABDX
Want to see GB:ABDX full AI Analyst Report?
Top Page
Abingdon Health PLC
(LSE:ABDX)
Select Model
Select Model
Rating:50Neutral
Price Target:
12.50 p
▲(100.00% Upside)
Action:Reiterated
Date:05/07/26
The score is held back primarily by weak financial quality—ongoing losses, declining gross margin, and negative operating cash flow—despite strong revenue growth. Technicals are supportive with the price above major moving averages and a positive MACD, but elevated RSI indicates potential near-term overheating. Valuation is constrained by negative earnings and the absence of a dividend yield.
Positive Factors
Strong revenue growth
Revenue growth above 40% indicates durable expansion in demand for Abingdon's diagnostic products and services. Sustained top-line growth helps absorb fixed manufacturing costs, supports scale advantages, and can enable future margin recovery as volumes normalize over the next 2–6 months.
Negative Factors
Negative operating cash flow
Operating activities consume cash despite positive FCF growth metrics, indicating the business currently fails to convert revenue into sustainable cash. Continued negative operating cash flow will likely require external financing or equity issuance to fund working capital and capex needs over months.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong revenue growth
Revenue growth above 40% indicates durable expansion in demand for Abingdon's diagnostic products and services. Sustained top-line growth helps absorb fixed manufacturing costs, supports scale advantages, and can enable future margin recovery as volumes normalize over the next 2–6 months.
Read all positive factors
Abingdon Health PLC (ABDX) vs. iShares MSCI United Kingdom ETF (EWC)
Market Cap
£30.13M
Dividend YieldN/A
Average Volume (3M)78.74K
Price to Earnings (P/E)―
Beta (1Y)-0.10
Revenue Growth40.37%
EPS Growth-13.70%
CountryUK
Employees113
SectorHealthcare
Sector Strength45
IndustryMedical - Diagnostics & Research
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding251,077,850
10 Day Avg. Volume45,332
30 Day Avg. Volume78,736
Financial Highlights & Ratios
PEG Ratio-0.06
Price to Book (P/B)4.84
Price to Sales (P/S)3.04
P/FCF Ratio-7.48
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)>-0.01
Revenue Forecast (FY)£12.18M
Abingdon Health PLC Business Overview & Revenue Model
Company Description
Abingdon Health PLC (ABDX) is a UK-based company specializing in the development and manufacture of rapid diagnostic tests. The company focuses on providing innovative solutions in the healthcare sector, particularly in the fields of infectious di...
How the Company Makes Money
Abingdon Health makes money primarily by providing contract development and manufacturing services for rapid diagnostic tests, especially lateral flow immunoassays. Key revenue streams typically include: (1) Contract assay development and product ...
Abingdon Health PLC Financial Statement Overview
Summary
Income Statement
45
Neutral
Balance Sheet
50
Neutral
Cash Flow
40
Negative
| Breakdown | TTM | Jun 2025 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 9.57M | 8.43M | 4.04M | 2.83M | 11.62M | 5.24M |
| Gross Profit | 3.27M | 3.13M | 1.40M | -5.23M | 3.39M | 4.09M |
| EBITDA | -2.98M | -3.12M | -2.81M | -19.98M | -6.07M | -2.84M |
| Net Income | -3.24M | -3.42M | -3.47M | -21.26M | -6.97M | -3.37M |
Balance Sheet | ||||||
| Total Assets | 10.55M | 9.31M | 6.06M | 12.77M | 33.23M | 10.97M |
| Cash, Cash Equivalents and Short-Term Investments | 3.71M | 1.92M | 3.24M | 2.40M | 4.98M | 4.39M |
| Total Debt | 948.00K | 1.03M | 1.02M | 1.28M | 1.50M | 4.77M |
| Total Liabilities | 4.25M | 4.01M | 3.05M | 6.34M | 11.90M | 8.22M |
| Stockholders Equity | 6.30M | 5.30M | 3.01M | 6.43M | 21.33M | 2.75M |
Cash Flow | ||||||
| Free Cash Flow | -2.59M | -3.43M | 845.00K | -8.49M | -20.13M | 445.00K |
| Operating Cash Flow | -2.24M | -3.10M | 1.00M | -7.74M | -12.88M | 2.10M |
| Investing Cash Flow | -365.00K | -1.43M | -156.00K | -760.00K | -7.28M | -1.94M |
| Financing Cash Flow | 2.65M | 5.08M | -7.00K | 5.92M | 20.74M | 3.37M |
Abingdon Health PLC Technical Analysis
Positive
6.25
Price Trends
9.13
Positive
7.72
Positive
7.05
Positive
Market Momentum
0.89
Positive
59.54
Neutral
48.33
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:ABDX, the sentiment is Positive. The current price of 6.25 is below the 20-day moving average (MA) of 10.79, below the 50-day MA of 9.13, and below the 200-day MA of 7.05, indicating a bullish trend. The MACD of 0.89 indicates Positive momentum. The RSI at 59.54 is Neutral, neither overbought nor oversold. The STOCH value of 48.33 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for GB:ABDX.
Abingdon Health PLC Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
68 Neutral | £252.42M | 63.85 | 10.14% | 3.40% | 16.51% | 97.67% | |
59 Neutral | £116.24M | 166.23 | 3.01% | ― | 2.73% | -65.94% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | £30.13M | -2.69 | -55.91% | ― | 40.37% | -13.70% | |
50 Neutral | £4.88M | -4.58 | 12.15% | ― | -10.20% | 714.29% | |
49 Neutral | £17.66M | -0.76 | -153.92% | ― | 65.60% | 74.84% | |
39 Underperform | £7.87M | ― | 425.97% | ― | ― | ― |
* Healthcare Sector Average
GB:ABDX
Abingdon Health PLC
11.50
5.40
88.52%
GB:NIOX
Circassia Pharmaceuticals
60.80
-7.00
-10.32%
GB:EKF
EKF Diagnostics Holdings
26.70
0.60
2.30%
GB:GDR
Genedrive
1.10
-0.23
-17.54%
GB:CNSL
Omega Diagnostics
2.05
-0.50
-19.61%
GB:RENX
Renalytix
1.80
-6.70
-78.82%
Abingdon Health PLC Corporate Events
Business Operations and StrategyProduct-Related Announcements
Abingdon Health Advances Co-Developed Companion Diagnostic with 4TEEN4
Positive
May 6, 2026
Abingdon Health has provided a detailed update on its collaboration with German biopharmaceutical firm 4TEEN4 Pharmaceuticals to develop DPP3 InvoSelect, a lateral flow-based companion diagnostic for invobenitug, an antibody therapy targeting life...
Business Operations and StrategyDelistings and Listing Changes
Abingdon Health Begins OTCQB Trading to Expand U.S. Investor Access
Positive
Apr 21, 2026
Abingdon Health plc, a specialist in rapid diagnostic test development, manufacturing and regulatory services, has an international footprint with headquarters in York, UK, laboratories in Doncaster, and laboratories and commercial offices in Madi...
Business Operations and Strategy
Abingdon Health Awards EMI Share Options to UK Staff
Positive
Apr 15, 2026
Abingdon Health plc, a leading international developer, manufacturer and regulatory services provider for rapid diagnostic tests and med‑tech, operates as a contract development and manufacturing organisation for lateral flow assays, taking ...
Business Operations and StrategyDelistings and Listing Changes
Abingdon Health to Begin OTCQB Trading as It Expands US Footprint
Positive
Apr 14, 2026
Abingdon Health plc, a UK-headquartered med-tech CDMO focused on lateral flow diagnostics and regulatory services, serves an international client base from sites in York and Doncaster in England and Madison, Wisconsin in the USA. Its operations sp...
Business Operations and Strategy
Abingdon Health Wins £4.8m U.S. Contracts for Multiplex Lateral Flow Systems
Positive
Mar 30, 2026
Abingdon Health has secured approximately £4.8m of contracts from a US-based customer to develop and scale up several multiplex quantitative lateral flow assay systems that can measure multiple biomarkers in human samples. The 27‑month ...
Business Operations and StrategyFinancial Disclosures
Abingdon Health lifts revenues 45% and targets profitable second half
Positive
Mar 17, 2026
Abingdon Health reported unaudited first-half FY26 revenues of £4.5 million including grants, a 45% increase year-on-year, with reported revenue up 37% to £4.2 million and a reduced loss before tax of £2.3 million. The company said ...
Business Operations and Strategy
Abingdon Health Wins $2.5m Clinical Self-Test Contract, Bolstering Diagnostics Role
Positive
Mar 12, 2026
Abingdon Health plc, a U.K.-based med-tech contract service provider, focuses on the development, manufacturing and regulatory support of rapid diagnostic tests, particularly lateral flow and other in vitro diagnostic assays. Serving international...
Business Operations and StrategyDelistings and Listing Changes
Abingdon Health Targets US Investors With OTCQB Listing After Wisconsin Expansion
Positive
Mar 10, 2026
Abingdon Health is deepening its US presence by securing quotation for its ordinary shares on the OTCQB Venture Market under the ticker ABDXF, complementing its existing AIM listing in London. The move allows trading in US dollars during US market...
Business Operations and StrategyFinancial Disclosures
Abingdon Health Sets Date for Interim Results and Investor Presentation
Neutral
Mar 5, 2026
Abingdon Health plc, an AIM-quoted international developer, manufacturer and regulatory services provider for rapid diagnostic tests and med-tech, focuses on contract development and manufacturing of lateral flow assays and associated regulatory a...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.